Briefing on the Fundamentals of Moderna (MRNA)

Large-cap health care company Moderna has moved 4.3% this afternoon, reaching $113.31 per share. In contrast, the average analyst target price for the stock is $168.76.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in the United States.

Make Sure to Consider the Following Before Buying Moderna:

  • Moderna has moved -17.0% over the last year.

  • MRNA has a forward P/E ratio of -22.8 based on its EPS guidance of -4.97.

  • Over the last 5 years, earnings per share (EPS) have been growing at a compounded average rate of 9.4%.

  • The company has a price to earnings growth (PEG) ratio of 0.61.

  • Its Price to Book (P/B) ratio is 2.55

Moderna Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023-02-24 4,981,000 -400,000 5,381,000 -61.3
2022-02-25 13,620,000 -284,000 13,904,000 563.68
2021-02-26 2,027,000 -68,000 2,095,000 590.63
2020-02-27 -459,000 -32,000 -427,000 -89.69
2019-02-06 -330,865 -105,766 -225,099

Moderna's free cash flows have a decent average of $4.15 Billion over the last 5 years, but they are highly variable since their coefficient of variability is 2958439515.2%. The compounded average growth rate over this period is 0.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS